REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to ...
REGENXBIO (RGNX) stock plunges after FDA clinical hold on RGX-111/RGX-121 gene therapies over a tumor case. Read more here.
Stocktwits on MSN
RGNX shares pare losses as Wall Street dismisses gene therapy clinical hold spurred selloff as an overreaction
Leerink said the premarket selloff in shares underscores the degree of surprise on the news, feeding into the "FDA ...
As of Wednesday, January 28, REGENXBIO Inc.’s RGNX share price has dipped by 18.49%, which has investors questioning if this is right time to buy.
The company said that the FDA hold has impacted two experimental gene therapies, RGX-111 and RGX-121. ・REGENXBIO added that ...
Jan 28 (Reuters) - Regenxbio said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its ...
The US Food and Drug Administration (FDA) has placed a clinical hold on Regenxbio’s investigational gene therapy, RGX-111, ...
REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its ...
Investing.com -- REGENXBIO Inc. (NASDAQ:RGNX) stock fell 28% Wednesday after the FDA placed clinical holds on two of its ...
The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing ...
A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...
Shares of Regenxbio plunged after the Food and Drug Administration placed clinical holds on two drug development programs after a five-year-old participant in one study developed an intraventricular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results